ENXTPA:SANPharmaceuticals
Sanofi (ENXTPA:SAN) Valuation After Strong Results Buyback Expansion Dividend Hike And Positive Amlitelimab Data
Why Sanofi’s latest update matters for shareholders
Sanofi (ENXTPA:SAN) has put several moving pieces on the table at once, with fresh 2025 results, higher shareholder payouts, a larger buyback, new 2026 guidance, and late stage amlitelimab data all landing together.
See our latest analysis for Sanofi.
Sanofi’s latest set of updates, including the amlitelimab phase 3 readouts, higher dividend, larger buyback and 2026 guidance, arrives after a period where momentum has cooled. The 90 day share...